Compumedics (ASX: CMP) surges as FY27 growth replaces guidance doubt

Compumedics Limited (ASX: CMP) shares jumped 14.6% to around A$0.275 during Monday trading after the medical technology company revealed record FY26 shipped and invoiced revenue of approximately A$60.3 million. The company delivered revenue growth of about 18%, while recurring revenue from its Somfit and Nexus 360 platforms increased approximately 70%. However, the result remained below the revised A$62 million to A$65 million guidance range, following an earlier ambition to generate around A$70 million. The next test for investors is whether delayed MEG revenue, the United States launch of Somfit D and stronger recurring revenue can produce faster EBITDA growth in FY27.

Why did Compumedics shares surge after record FY26 revenue despite another guidance shortfall?

The immediate explanation for the Compumedics share price rally is that the FY26 update removed some of the uncertainty that had weighed on the stock. Revenue reached a record A$60.3 million, sales orders remained healthy at approximately A$62.7 million and the company entered FY27 with an active order book across sleep diagnostics, neurology, connected platforms and magnetoencephalography, or MEG. Investors were also told that the helium availability and pricing problem delaying MEG installations had been resolved.

The market reaction therefore appears to reflect relief rather than an unquestioned endorsement of the entire result. Compumedics had originally targeted approximately A$70 million of FY26 revenue and EBITDA of up to A$9 million. It reduced the revenue outlook in April to between A$62 million and A$65 million, with EBITDA of A$5.5 million to A$7 million, before ultimately reporting approximately A$60.3 million of unaudited revenue.

That progression matters because small-cap medical technology companies are often valued on management’s ability to translate product demand into recognised revenue, cash flow and earnings. Compumedics has demonstrated that demand exists, but investors have repeatedly had to adjust expectations around when revenue will arrive. The rally suggests that shareholders currently accept the timing explanation, particularly because delayed MEG activity could move into FY27 rather than disappear completely.

There is nevertheless an important omission in the latest update. Compumedics said FY26 EBITDA was expected to grow, but it did not provide a precise preliminary EBITDA figure. The share price may have responded to the headline revenue and recurring-revenue growth, but the audited results will need to demonstrate that higher sales are producing meaningful operating leverage.

What makes Compumedics different from other small-cap medical technology companies on the ASX?

Compumedics is not a pre-revenue medical device developer waiting for a single regulatory approval. It is an established diagnostic technology company selling products across sleep medicine, neurology, brain research and ultrasonic blood-flow monitoring. Its portfolio includes traditional clinical equipment, connected software platforms, consumables, service revenue and higher-value MEG systems.

The most strategically important platform for the retail investment thesis is Somfit. The system supports home sleep testing and uses electroencephalography signals to capture sleep architecture, giving clinicians information that simpler respiratory monitoring systems may not provide. Compumedics offers both a reusable Somfit platform and Somfit D, a single-use version designed for large-scale deployment in the United States home sleep testing market.

Nexus 360 adds a software and connectivity layer by allowing sleep and neurological diagnostic data to be managed through a connected platform. This creates an opportunity for Compumedics to build recurring software revenue on top of its installed hardware base. The approximately 70% increase in combined Somfit and Nexus 360 recurring revenue during FY26 is therefore more important than the percentage alone suggests. It indicates that the company is gradually changing the quality of its revenue rather than relying exclusively on equipment sales.

The Orion LifeSpan MEG platform provides a different type of growth opportunity. MEG systems are sophisticated brain-imaging installations with high individual contract values, but manufacturing, shipment, installation and customer acceptance can occur over extended periods. These projects can materially lift revenue and earnings when delivered, yet they also introduce timing volatility that makes quarterly or even annual forecasting more difficult.

This combination of connected sleep diagnostics, clinical software and high-value brain-imaging equipment gives Compumedics several ways to grow. It also creates operational complexity. The company must simultaneously manage disposable-device manufacturing, software adoption, medical equipment sales, international distribution and large MEG projects. Differentiated technology is useful, but shareholders ultimately need evidence that the portfolio can be commercialised without recurring delays.

How strong were the FY26 numbers once revenue growth, order intake and earnings quality are separated?

The headline FY26 revenue result was encouraging. Revenue increased approximately 18% from A$51 million in FY25 to around A$60.3 million in FY26. This was achieved despite slower-than-expected MEG installations and the delayed commercial release of Somfit D in the United States, suggesting that the existing sleep, neurology, service and connected-platform businesses continued to expand.

Recurring-revenue growth was the standout feature. Somfit and Nexus 360 SaaS recurring revenue increased approximately 70% compared with FY25, even though Somfit D had not entered full United States commercial release. That growth should improve revenue visibility, customer retention and gross-margin potential if Compumedics can continue scaling without adding costs at the same rate.

Sales orders of approximately A$62.7 million were broadly aligned with recognised revenue, creating an estimated book-to-bill ratio of about 1.04 times. A ratio above one indicates that incoming orders slightly exceeded shipped and invoiced revenue. However, FY26 order intake was marginally below the A$63.4 million recorded in FY25, meaning the order number points to stability rather than rapid acceleration.

The missing EBITDA figure prevents investors from fully judging earnings quality. Compumedics produced A$3.1 million of EBITDA in the first half, compared with A$0.7 million a year earlier, and returned to a small net profit. The full-year result now needs to show that the second half preserved that improvement despite revenue finishing below revised guidance.

Cash conversion will be equally important. MEG projects and equipment shipments can require inventory, manufacturing expenditure and working capital before revenue is recognised or customer payments are collected. A business growing revenue but consuming increasing amounts of cash would deserve a lower valuation than one converting recurring software and service income into reliable free cash flow.

What milestones must Compumedics deliver before the next major FY27 share price catalyst?

The first milestone will be the preliminary full-year result expected in late August 2026. Investors will be looking for the audited revenue number, the final EBITDA result, gross-margin performance, operating cash flow, net debt and working-capital position. These figures will determine whether the FY26 update represents a genuine improvement in earnings quality or mainly a strong top-line result.

The second milestone is continued conversion of existing MEG orders. Compumedics has said that the helium-related issue affecting shipment and installation schedules has been resolved, while recent MEG invoicing was completed in June. The FY27 evidence investors need is a clear sequence of manufacturing completion, shipment, installation, customer acceptance and revenue recognition.

Somfit D is the third and potentially more scalable catalyst. Manufacturing commitments are now in place, but the product still needs to complete the remaining commercial-readiness steps before broader United States release. Initial provider adoption, order volumes, test utilisation and recurring revenue per study will matter more than another broad statement about the size of the market.

The appointment of Michael Stone as Chief Commercial Officer for the United States operations adds another execution marker. His priorities include strengthening the sleep and neurodiagnostics sales organisations and expanding the commercial reach of Somfit. Investors should watch whether new commercial leadership produces identifiable customer wins and accelerating United States orders during FY27.

Management is targeting further double-digit FY27 revenue growth and EBITDA growth at a faster rate than sales. That is the central promise behind the current rerating attempt. The stock is more likely to sustain today’s gains if each update shows improving margins and cash conversion rather than simply shifting undelivered revenue into another reporting period.

Is the Compumedics share price still cheap after the rally when measured against revenue and execution risk?

At around A$0.275 per share, Compumedics carried an estimated market capitalisation of roughly A$55 million during Monday trading. That valuation is equivalent to approximately 0.9 times the company’s preliminary FY26 revenue of A$60.3 million. Even at the intraday high of A$0.295, the market capitalisation remained close to annual revenue.

A sub-one-times revenue valuation can appear inexpensive for a medical technology company reporting double-digit growth and rapidly expanding recurring revenue. However, revenue multiples cannot be considered without margins, cash generation and predictability. Compumedics is not yet being valued like a mature software business because a substantial part of its revenue still comes from equipment, installations and projects with variable delivery schedules.

The share price performance also shows that the market has not fully forgotten earlier disappointment. At A$0.275, the stock was around 10% above its 29 June close of A$0.25 and approximately 7.8% above its 5 June close of A$0.255. However, it remained around 19% below its A$0.34 starting price for 2026 and approximately 39% beneath the 52-week high of A$0.45. The 52-week trading range has been approximately A$0.23 to A$0.45.

Published consensus data is based on very limited analyst coverage, with a one-analyst target near A$0.80. That target illustrates the potential valuation gap if Compumedics delivers its growth plan, but a single estimate should not be treated as a reliable market consensus. Small-cap targets can change substantially when earnings forecasts, timing assumptions or capital requirements shift.

The more useful valuation framework is scenario-based. A successful FY27 featuring double-digit revenue growth, recurring-revenue expansion, multiple MEG deliveries and faster EBITDA growth could justify a material rerating. A year of respectable sales growth but weak cash conversion may leave the stock near a revenue multiple of around one. Further delays or another guidance reduction could quickly reverse the relief rally.

How could home sleep testing demand, reimbursement trends and helium supply shape the investment thesis?

The structural move toward home-based diagnostics supports the Compumedics investment case. Healthcare systems are looking for ways to diagnose more patients without requiring every sleep study to be conducted in a hospital laboratory. Home testing can reduce costs, improve patient convenience and expand testing capacity, particularly when devices integrate clinical data with cloud-based interpretation and workflow software.

Somfit and Somfit D are positioned around this shift. The reusable product can suit multi-night or repeat testing models, while the single-use Somfit D is intended for higher-volume workflows where providers prefer disposable devices. The opportunity is significant, but United States reimbursement policies, provider purchasing behaviour and competitive pricing will influence adoption.

Regulatory clearance provides access to the market but does not guarantee commercial scale. Compumedics must prove that providers find the system easy to distribute, patients use it correctly, clinicians trust the data and reimbursement supports an attractive economic model. Competitors may also reduce prices or improve their own diagnostic capabilities as home sleep testing expands.

MEG operates under a different macro environment. Demand depends partly on research budgets, hospital capital spending, government-backed institutions and major neurological programmes. Large orders can create multi-year revenue visibility, but installations require specialised components and careful coordination with customers.

The recent helium disruption demonstrates how geopolitical and commodity-market developments can affect a highly specialised medical technology supplier. Compumedics has said the immediate issue is resolved, but helium availability and pricing remain external risks. Currency movements across the Australian dollar, United States dollar, euro and Chinese yuan can also influence reported revenue, costs and contract economics.

Why are retail investors watching ASX and what does the current market sentiment reveal?

Compumedics has several features that naturally attract retail investor attention. It is a small-cap medical technology company with commercial products, global customers, regulatory clearances and multiple potential catalysts. Its market capitalisation remains modest relative to annual revenue, while recurring-revenue growth creates the possibility of a higher valuation if earnings become more predictable.

Public retail discussion has concentrated on the same tension now visible in the share price. Optimistic investors focus on the approximately 70% recurring-revenue growth, the United States opportunity for Somfit D, the MEG order book and a valuation near one times revenue. More cautious investors point to repeated guidance changes, delayed revenue conversion and the absence of a precise FY26 EBITDA number.

Monday’s trading demonstrates how quickly sentiment can change in a stock with relatively limited liquidity. The shares moved from the previous A$0.24 close to an intraday high of A$0.295 before trading around A$0.275. Such a wide intraday range can create strong percentage gains, but it also means late buyers may experience substantial volatility even when the fundamental announcement is positive.

The company also has a concentrated share register, which can reduce the effective public float. Lower free float can magnify price reactions when new buyers enter following an announcement. It can equally intensify declines when investors attempt to exit during a period of disappointing news.

Retail investors should therefore separate the business catalyst from the trading catalyst. Record revenue and recurring-revenue growth improve the fundamental story. The immediate price spike, however, may also reflect thin liquidity, short-term momentum and traders reacting to the ASX gainer list. Sustainable upside requires FY27 execution to catch up with the valuation narrative.

What execution risks could prevent Compumedics from converting FY27 growth into a lasting rerating?

Guidance credibility is the most visible risk. Compumedics moved from an original FY26 revenue target of approximately A$70 million to a revised range of A$62 million to A$65 million before reporting approximately A$60.3 million. The underlying reasons may be timing-related, but investors will demand greater forecasting discipline before assigning the stock a premium multiple.

MEG remains both a major opportunity and a source of lumpiness. Revenue depends on manufacturing, shipment, installation and customer acceptance, while each system can materially affect annual results. Additional delays caused by components, helium, site readiness or institutional schedules could again push revenue between reporting periods.

Somfit D has commercial risk despite regulatory clearance. Manufacturing must scale reliably, the United States sales organisation must secure provider adoption and utilisation must generate recurring software and consumable revenue. A product can be technologically differentiated without achieving rapid market penetration, especially in a competitive and reimbursement-sensitive healthcare market.

Working capital is another consideration. Compumedics reported available liquidity headroom of approximately A$10 million to A$11 million in April following MEG cash receipts and expanded facilities. The audited result needs to confirm that inventory, receivables and product-launch expenditure remain manageable as the company grows.

The resignation of Non-Executive Director Christopher Barys, effective 30 June 2026, is not necessarily a negative operating signal, but it adds a governance development to monitor. Barys had experience in United States medical technology, commercial strategy and capital markets. Board composition and commercial oversight will matter as Compumedics attempts to scale its United States operations.

The core investment question is therefore not whether Compumedics owns valuable technology. The stronger question is whether the company can transform that technology into predictable revenue, widening margins and positive cash flow. FY27 may provide the clearest answer yet.

Key takeaways for investors assessing the Compumedics (ASX: CMP) share price after the FY26 update

• Compumedics (ASX: CMP) delivered record preliminary FY26 revenue of approximately A$60.3 million, representing growth of about 18%, but the result remained below revised guidance of A$62 million to A$65 million.
• Somfit and Nexus 360 recurring revenue increased approximately 70%, strengthening the argument that the company’s revenue mix is becoming more scalable and predictable.
• FY26 orders of approximately A$62.7 million produced an estimated book-to-bill ratio of about 1.04 times, although order intake was slightly below the A$63.4 million achieved in FY25.
• The next major catalysts are the audited full-year result, MEG revenue conversion, Somfit D’s United States commercial release and evidence that EBITDA is growing faster than revenue.
• At around A$0.275, Compumedics was valued at approximately A$55 million, or roughly 0.9 times preliminary FY26 revenue, but execution risk explains part of the apparent discount.
• The primary risks are further timing delays, weak cash conversion, slower Somfit D adoption, MEG project volatility and reduced confidence following repeated guidance revisions.